Selective Optimization of Side Activities: Another Way for Drug Discovery

Journal of Medicinal Chemistry

Volumn 47, Issue 6, 2004, Pages 1303-1314

  Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 2 (2 AMINOETHOXYMETHYL) 6 ETHYL 1,4 DIHYDRO 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 AMIDE 3 [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE; 3,4 DIHYDRO 3 HYDROXY 6 METHYL 1,5 BENZOXAZOCINE; 4 (3,4 DIFLUOROPHENYL) 3,4 DIHYDRO 6 METHOXYMETHYL 2(1H) OXO 3,5 PYRIMIDINEDICARBOXYLIC ACID 5 METHYL ESTER 3 [3 [4 (2 PYRIDYL) 1 PIPERIDINYL]PROPYL]AMIDE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; AMILORIDE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BMS 193884; CALCIUM CHANNEL BLOCKING AGENT; CLOZAPINE; CROMAKALIM; DEXNIGULDIPINE; HALOPERIDOL; NATURAL PRODUCT; NEUROLEPTIC AGENT; NEW DRUG; NIGULDIPINE; OLANZAPINE; OXAZOCINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE; SODIUM PROTON EXCHANGE PROTEIN; SULFATHIAZOLE; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ANALYTIC METHOD; BINDING AFFINITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; METHODOLOGY; NONHUMAN; REVIEW; SIDE EFFECT;

ANIMALS; BIOLOGICAL AVAILABILITY; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; PATENTS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1542268206     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030480f     Document Type: Review

References (87)

1. Raju, T. N. K. Nobel Chronicles. Lancet 2000, 355.
2. Liu, K.; Xu, L.; Szalkowski, D.; Li, Z.; Ding, V.; Kwei, G.; Huskey, S.; Moller, D. E.; Heck, J. V.; Zhang, B. B.; Jones, A. B. Discovery of a Potent, Highly Selective, and Orally Efficacious Small-Molecule Activator of the Insulin Receptor. J. Med. Chem. 2000, 43, 3487-3494.
3. Roever, S.; Adam, G.; Cesura, A. M.; Galley, G.; Jenck, F.; Monsma, F. J., Jr.; Wichmann, J.; Dautzenberg, F. M. High-Affinity, Non-Peptide Agonists for the ORL1 (Orphanin FQ/ Nociceptin) Receptor. J. Med. Chem. 2000, 43, 1329-1338.
4. Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; Stallings, W. C.; Connolly, D. T.; Shoichet, B. K. Molecular docking and high throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 2002, 45, 2213-2221.
5. Youngman, M. A.; McNally, J. J.; Lovenberg, T. W.; Reitz, A. B.; Willard, N. M.; Nepomuceno, D. H.; Wilson, S. J.; Crooke, J. J.; Rosenthal, D.; Vaidya, A. H.; Dax, S. L. N-(Sulfonamido)-alkyl-β-aminotetralins: Potent and Selective Neuropeptide Y Y5 Receptor Antagonists. J. Med. Chem. 2000, 43, 346-350.
6. Song, Y.; Connor, D. T.; Sercel, A. D.; Sorenson, R. J.; Doubleday, R.; Unangst, P. C.; Roth, B. D.; Beylin, B. G.; Gilbertsen, R. B.; Chan, K.; Schrier, D. J.; Guglietta, A.; Bornemeier, D. A.; Dyer, R. D. Synthesis, Structure-Activity Relationships and in Vivo Evaluations of Substituted Di-tert-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 Inhibitors. 2. 1,3,4- and 1,2,4-Thiadiazole Series. J. Med. Chem. 1999, 42, 1161-1169.
7. Gilligan, P. J.; Robertson, D. W.; Zaczek, R. Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents. J. Med. Chem. 2000, 43, 1641-1660.
8. Baxter, A.; Bennion, C.; Bent, J.; Boden, K.; Brough, S.; Cooper, A.; Kinchin, E.; Kindon, N.; McInally, T.; Mortimore, M.; Roberts, B.; Unitt, J. Hit-to-Lead Studies: The Discovery of Potent, Orally Bioavailable, Triazolethiol CXCR2 Receptor Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 2625-2628.
9. Wermuth, C. G. Search for New Lead Compounds: The Example of the Chemical and Pharmacological Dissection of Aminopyridazines. J. Heterocycl. Chem. 1998, 35, 1091-1100.
10. Wermuth, C. G.; Clarence-Smith, K. "Drug-like" Leads: Bigger Is Not Always Better. Pharm. News 2000, 7, 53-57.
11. Wermuth, C. G. The "SOSA" Approach: An Alternative to High-Throughput Screening. Med. Chem. Res. 2001, 10, 431-439.
12. Wermuth, C. G. Strategies in the search for new lead compounds or original working hypotheses. The Practice of Medicinal Chemistry, 2nd ed.; Academic Press: London, 2003.
13. Sosa, S. When we proposed the acronym "SOSA", we were not aware of the existence of a famous baseball player Sammy SOSA, well-known for his homerun hitting. Hitting the target is our common objective.
14. Prestwick-Chemical (Washington, DC), Prestwick Chemical Library. www.prestwickchemical.com.
15. Sigma-RBI Lopac (library of pharmacologically active compounds). ligands@sial.com.
16. MicroSource Genesis-Plus Library. compounds@aol.com.
17. Beer, B.; Chasin, M.; Clody, D. E.; Vogel, J. R.; Horovitz, Z. P. Cyclic Adenosine Monophosphate Phosphodiesterase in Brain: Effect on Anxiety. Science 1972, 176, 428-430.
18. Luque, J. M.; Erat, R.; Kettler, R.; Cesura, A.; Da Prada, M.; Richards, J. G. Radioautographic evidence that the GABA-A receptor antagonist SR 95531 is a substrate inhibitor of MAO-A in the rat and human locus coeruleus. Eur. J. Neurosci. 1994, 6, 1038-1049.
19. Olsen, R. W.; Ticku, M. K.; Greenlee, D.; Van Ness, P. GABA Receptor and Ionophore Binding Sites: Interaction with Various Drugs. GABA-Neurotransmitters: Pharmacological, Biochemical and Pharmacological Aspects; Munksgaard: Copenhagen, 1979; pp 165-178.
20. G-Nitro L-Arginine Methyl Ester and Other Alkyl Esters of Arginine Are Muscarinic Receptor Antagonists. Circ. Res. 1993, 72, 387-395.
21. Hoyer, D. 5-Hydroxytryptamine receptors and effector mechanisms in peripheral tissues. Peripheral Actions of 5-HT; Oxford University Press: Oxford, 1989; pp 72-99.
22. Bymaster, F. P.; Calligaro, D. O.; Falcone, J. F.; Marsh, R. D.; Moore, N. A.; Tye, N. C.; Seeman, P.; Wong, D. T. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine. Neuropsychopharmacology 1996, 14, 87-96.
23. Schaus, J. M.; Bymaster, F. P. Dopaminergic Approaches to Antipsychotic Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, CA, 1998; pp 1-10.
24. Stein, P. D.; Hunt, J. T.; Floyd, D. M.; Moreland, S.; Dickinson, K. E. J.; Mitchell, C.; Liu, E. C.-K.; Webb, M. L.; Murugesan, N.; Dickey, J.; McMullen, D.; Zhang, R.; Lee, V. G.; Serdino, R.; Delaney, C.; Schaeffer, T. R. ; Kozlowski, M. The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ETA Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazoly1)-l-naphthalenesulfonamide. J. Med. Chem. 1994, 37, 329-331.
25. A Selective Antagonist. J. Med. Chem. 2003, 46, 125-137.
26. + exchange: Structure, regulation, and its role in heart disease. Circ. Res. 1999, 85, 777-786.
27. +, exchange. Am. J. Physiol. 1988, 255, H608-H615.
28. + exchanger. Drugs 1999, 2, 1009-1025.
29. + antiport inhibitors. J. Med. Chem. 1997, 40, 2017-2034.
30. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for Drug Discovery: Development of Potent, Selective, Orally Effectice Cholecystin Antagonists. J. Med. Chem. 1988, 31, 2235-2246.
31. Patchett, A. A.; Nargund, R. P. Privileged Structures-An Update. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, CA, 2000; pp 289-298.
32. Sheridan, R. P.; Miller, M. D. A Method for Visualizing Recurrent Topological Substructures in Sets of Active Molecules. J. Chem. Inf. Comput. Sci. 1998, 38, 915-924.
33. Thompson, L. A.; Ellman, J. A. Synthesis and Applications of Small Molecule Libraries. Chem. Rev. 1966, 96, 555-600.
34. Lagu, B. Identification of a1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia. Drugs Future 2001, 26, 757-765.
35. 1-Adrenergic Antagonist Binding. J. Biol. Chem. 2001, 276, 25366-253711.
36. 1A-antagonists. Bioorg. Med. Chem. Lett. 1998, 9, 2843-2848.
37. Anonymous. Monatepil maleate. Drugs Future 1988, 13, 211.
38. Anonymous. Monatepil maleate. Drugs Future 1997, 22, 440.
39. 1-adrenoceptor antagonist monatepil maleate. Arzneim.-Forsch. 1996, 46, 378-381.
40. Robinson, K. A.; Robinson, C. P.; Castaner, J. Dexniguldipine Hydrochloride. Drugs Future 1997, 22, 114-122.
41. Amschler, H.; Flockerzi, D.; Klemm, K. (Byk Gulden Lomberg Chem. Fabrik GmbH). 1,4-Dihydropyridine enantiomers. AU 8816264, EP 296316, EP 343193, WO 8807525, 1988.
42. Klemm, K.; Ulrich, W.-R.; Flockerzi, D.; Sanders, K.; Beller, K.-D. (Gyk Gulden Lomberg Chem. Fabrik GmbH). Optically pure (R)-(+)-niguldipine and its derivatives for treating tumor diseases. WO 8907443, 1989.
43. Gros, P.; Croop, J.; Roninson, I.; Varshavasky, A.; Houseman, D. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 337-341.
44. 1-adrenoreceptors. Eur. J. Pharmacol., Mol. Pharmacol. Sect. 1989, 172, 131-146.
45. 3H]-vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur. J. Pharmacol. 1994, 288, 105-114.
46. Überall, F.; Maly, K.; Egle, A.; Doppler, W.; Hofmann, J.; Grunicke, H. H. Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res. 1991, 51, 5821-5825.
47. Gietzen, K.; Abdallah, F.; Bai, G. Selective inhibition of proliferation by a novel dthydropyridine derivative with anti-calmodulin activity in the mammal tumor cell line ZR-75-1. Med. Sci. Res. 1990, 18, 627-629.
48. Fiebig, H. H.; Berger, D. P.; Dengler, W.; Licht, T.; Winterhalter, B.; Wallbrecher, E.; Sanders, K. H. B859-35, a new anticancer drug with MDR reversing properties. Ann. Oncol. 1992, 3 (Suppl. 1), 52.
49. Gekeler, V.; Wilisch, A.; Engelcke, M.; Probst, G.; Hofmann, J.; Neumann, M.; Probst, H. Effects of the new PKC inhibitor dexniguldipine-l-ICI (B859-035), an enantiomeric pure dihydropyridine, on DNA-replication and cell cycle. Proc. Am. Assoc. Cancer Res. 1993, 34, 2439.
50. Ukena, D.; Boewer, C.; Oldenkott, B.; Rathbeg, F.; Wurst, W.; Zech, K.; Sybrecht, G. W. Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCI after oral administration. A phase I dose-escalation trial. Cancer Chemother. Pharmacol. 1995, 36, 160-164.
51. Basil, B.; Coffee, E. C. J.; Gell, D. L.; Maxwell, D. R.; Sheffield, D. J.; Wooldridge, K. R. H. A New Class of Sympathic β-Receptor Blocking Agents. 3,4-Dihydro-3-hydroxy-1,5-benzoxazocines. J. Med. Chem. 1970, 13, 403-406.
52. Greenwood, D. T.; Mallion, K. B.; Todd, A. H.; Turner, R. W. 2-Aryloxymethyl-2,3,5,6-tetrahydro-1,4-oxazines, a new class of antidepressants. J. Med. Chem. 1975, 18, 573-577.
53. Evans, J. M.; Fake, C. S.; Hamilton, T. C.; Poyser, R. H.; Watts, E. A. Synthesis and Antihypertensive Activity of Substituted trans-4-Amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J. Med. Chem. 1983, 26, 1582-1589.
54. Evans, J. M.; Fake, C. S.; Hamilton, T. C.; Poyser, R. H.; Showell, G. A. Synthesis and Antihypertensive Activity of 6,7-Disubstituted trans-4-Amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J. Med. Chem. 1984, 27, 1127-1131.
55. Stemp, G.; Evans, J. M. Discovery and Development of Cromakalim and Related Potasssium Channel Activators. Medicinal Chemistry-The Role of Organic Chemistry in Drug Research, 2nd ed.; Academic Press: London, 1993; pp 141-162.
56. Ks channel blockers: potential antiarrhythmic agents. Drugs Future 2001, 26, 473-484.
57. + conductance. Pfluegers Arch. 1995, 429, 517-530.
58. Ks in guinea pig cardiac myocytes and guinea pig IKs channels by the chromanol 293B. Pfluegers Arch. 1996, 432, 1094-1096.
59. Ks channels by HMR1556. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362, 480-488.
60. Wermuth, C. G.; Bourguignon, J. J.; Hoffmann, R.; Boigegrain, R.; Brodin, R.; Kan, J. P.; Soubrié, P. SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome. Bioorg. Med. Chem. Lett. 1992, 2, 833-838.
61. Kan, J.-P.; Steinberg, R.; Oury-Donat, F.; Michaud, J.-C.; Thurneyssen, O.; Terranova, J.-P.; Gueudet, C.; Souilhac, J.; Brodin, R.; Boigegrain, R.; Wermuth, C. G.; Worms, P.; Soubrie, P.; Le Fur, G. SR 46559A: A novel and potent muscarinic compound with no cholinergic syndrome. Psychopharmacology 1993, 112, 219-227.
62. Contreras, J.-M.; Rival, Y. M.; Chayer, S.; Bourguignon, J. J.; Wermuth, C. G. Aminopyridazines as Acetylcholinesterase Inhibitors. J. Med. Chem. 1999, 42, 730-741.
63. Contreras, J.-M.; Parrot, I.; Sippl, W.; Rival, R. M.; Wermuth, C. G. Design, Synthesis and Structure-Activity Relationships of a Series of 3-[2-(1-Benzylpiperidin-4-yl)ethylamino]pyridazine Derivatives as Acetylcholinesterase Inhibitors. J. Med. Chem. 2001, 44, 2707-2718.
64. Gully, D.; Roger, P.; Valette, G.; Wermuth, C. G.; Courtemanche, G.; Gauthier, C. Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent (Alkylamino derivatives of thiazole: their synthesis and pharmaceutical properties) (Elf-Sanofi). French Demande No. 9207736 (patent application), June 24, 1992.
65. Gully, D.; Roger, P.; Wermuth, C. G. 4-Phenyl-aminothiazole derivatives, method for preparing same and pharmaceutical compositions containing said derivatives (Sanofi). World Patent WO9700868, January 9, 1997.
66. 3 agonist. Nature 1999, 400, 371-375.
67. 3 Receptors). Actual. Chim. 2003, 91-94.
68. 3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 1995, 275, 1239-1246.
69. Hrib, N. J. The dopamine D4 receptor: a controversial therapeutic target. Drugs Future 2000, 25, 587-611.
70. 4 receptor antagonists: Synthesis and structure-activity relationships of (S)-(+)-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl)amino] -2-methoxybenzamide (YM-43611). J. Med. Chem. 1996, 39, 2764-2772.
71. 4 receptor antagonist. NeuroReport 1996, 7, 2543-2546.
72. Sommer, C. Thalidomide as a blocker of TNF production. Drugs of the Future; Prous Science: Barcelona, Spain, 1999; pp 67-75.
73. Mellin, G.; Katzenstein, M. The Saga of Thalidomide. New. Engl. J. Med. 1962, 267, 1184-1193.
74. Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 1965, 6, 303-306.
75. Iyer, C. G. S.; Languillon, J.; Ramanujam, K. WHO coordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatus patients. Bull. W. H. O. 1971, 45, 719-732.
76. Baures, P. W.; Peterson, S. A.; Kelly, J. W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 1998, 6, 1389-1401.
77. Oza, V. B.; Smith, C.; Raman, P.; Koepf, E. K.; Lashuel, H. A.; Petrassi, H. M.; Chiang, K. P.; Powers, E. T.; Sachettinni, J.; Kelly, J. W. Synthesis, structure and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002, 45, 321-332.
78. Pepys, M. B.; Herbert, J.; Hutchinson, W. L.; Tennent, G. A.; Lachmann, H. J.; GallImore, J. R.; Lovat, L. B.; Bartfai, T.; Alanine, A.; Hertel, C.; Hoffmann, T.; Jakob-Roetne, R.; Norcross, R. D.; Kemp, J. A.; Yamamura, K.; Suzuki, M.; Taylor, G. W.; Murray, S.; Thomson, D.; Purvis, A.; Kolstoe, S.; Wood, S. P.; Hawkins, P. N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417, 254-259.
79. Riechers, H.; Albrecht, H.-P.; Amberg, W.; Baumann, E.; Böhm, H.-J. ; Klinge, D.; Kling, A.; Muller, S.; Raschack, M.; Unger, L.; Walker, N.; Wernet, W. Discovery and Optimization of a Novel Class of Orally Active Non-Peptidic Endothelin-A Receptor Antagonists. J. Med. Chem. 1996, 39, 2123-2128.
80. Aulabaugh, A.; Ding, W.-D.; Ellestad, G. A.; Gazumian, A.; Hess, C. D.; Krishnamurthy, G.; Mitsner, B.; Zaccardi, J. Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agents. Drugs Future 2000, 25, 287-294.
81. Ding, W.-D.; Mitsner, B.; Krishnamurthy, G. Novel and specific respiratory syncytial virus inhibitors that target virus fusion. J. Med. Chem. 1998, 41, 2671-2675.
82. Lipinski, C. A.; Lombardo, F.; Dominy, B. W. Experimental and computational approches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
83. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
84. Bergström, C. A. S.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 2003, 46, 558-570.
85. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physicochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
86. Shu, Y. Z.; Cutrone, J. Q.; Klohr, S. E.; Huang, S. BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346. II. Physicochemical properties and structural characterization. J. Antibiot. 1995, 48, 1060-1065.
87. Sim, M. F.; Yates, D. B.; Parkinson, R.; Cooling, M. J. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan, in conscious dogs and cats. Br. J. Pharmacol. 1988, 94, 371-380.